newsfilter
← Latest News
GlobeNewswire·

Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update

– Petosemtamab in combination with pembrolizumab interim data presented at 2024 ASCO® demonstrated robust 67% response rate among 24 evaluable patients – First patients dosed in phase 3 trial evaluating